A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
A Phase 1/2, Open Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination With Other Antileukemic Agents in Participants With Selected Myeloid Malignancies
The objective of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of S241656 and to determine the recommended dose for expansion (RDE) of S241656 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML), myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), or chronic myelomonocytic leukemia (CMML). Part 1A dose escalation will determine the RDE to be used in a future expansion stage of the trial. An optional Part 1B drug-drug interaction (DDI) substudy will evaluate the effect of posaconazole on the PK of S241656.
The study consists of a screening period of up to 21 days, a treatment period consisting of continuous 28-day cycles of treatment, an end-of-treatment visit, a safety follow-up period, and long-term disease and survival follow-up every 3 months. Participants in the optional DDI substudy may continue treatment in the main study following completion of the DDI assessment period. Participants may undergo bone marrow aspirates and/or biopsies, blood tests, electrocardiograms (ECGs), echocardiograms or multigated acquisition (MUGA) scans, physical examinations, ophthalmologic assessments, and disease response questionnaires.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Institut de Recherches Internationales Servier (I.R.I.S.)
- 电话号码:+33 1 55 72 60 00
- 邮箱:scientificinformation@servier.com
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
- Investigator-assessed life expectancy of ≥ 3 months.
- Able and willing to comply with requirements of the study protocol.
- Documented genetic characterization of the disease as per local practice.
- Clinical and laboratory thresholds:
- Cytoreduction: white blood cell (WBC) < 25 × 10⁹/L (hydroxyurea/cytarabine/leukapheresis allowed).
- Renal: creatinine clearance (CrCl) ≥ 60 mL/min (Cockcroft-Gault).
- Hepatic: aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN) (5 × if leukemic); Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN for Gilbert's syndrome).
- Part 1 Only: Relapsed/Refractory (R/R), pathologically confirmed AML, MDS/AML, or CMML.
- Part 1 Only: Must have failed ≥ 1 approved standard therapy and have no other approved standard options.
Exclusion Criteria:
- Known hypersensitivity to S241656, or Posaconazole (Part 1B).
- Pregnant or breastfeeding; positive serum pregnancy test for WOCBP.
- Diagnosis of acute promyelocytic leukemia (French-American-British [FAB] M3 classification), MPN, mixed/ambiguous lineage, histiocytic/dendritic cell neoplasms, or AML with isolated extramedullary disease (no marrow/blood involvement).
- Active Central Nervous System (CNS) disease (by cytologic or radiographic evidence).
- Failure to recover to ≤ Grade 1 from previous toxicities (except Grade 2 neuropathy/alopecia).
- Major surgery within 4 weeks.
- Any anticancer therapy within 2 weeks or 5 half-lives (28 days for biologics). Cytoreduction with hydroxyurea or cytarabine is permitted.
- Prior use of experimental KRAS/BRAF/MEK/ERK inhibitors (prior FLT3 inhibitors are permitted).
- Uncontrolled infections (human immunodeficiency virus (HIV)/hepatitis B virus (HBV)/hepatitis C virus (HCV) permitted only if viral load is undetectable/controlled and specific cluster of differentiation 4 (CD4)+ criteria are met).
- Malabsorption, Crohn's, or chronic vomiting that impacts oral drug absorption.
- History/risk of retinal vein occlusion (RVO), glaucoma, or hyper-viscosity syndromes.
- Other active malignancy requiring systemic therapy within 2 years (except non-melanoma skin cancer or localized/cured tumors).
- Stroke, myocardial infarction (MI), unstable angina, or acute coronary syndrome within 6 months.
- Congestive heart failure (CHF), clinically significant cardiac arrhythmias according to the investigator's judgement (e.g., ventricular tachycardia), complete left bundle branch block and high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II- and third degree AV block).
- Fridericia-corrected QT interval (QTcF) > 470 msec or history of Torsades de pointes.
- Disseminated intravascular coagulation (DIC), significant coagulopathy according to the investigator's judgement, or uncontrolled bleeding.
- Proton Pump Inhibitors (PPIs) and potassium-competitive acid blockers ≥ 7 days prior to Cycle 1 Day 1.
- Breast cancer resistance protein (BCRP) sensitive substrate or with a narrow therapeutic index (NTI)
- All herbal preparations/supplements are prohibited.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Part 1A: Dose Escalation
|
Tablets taken by mouth.
|
|
实验性的:Part 1B: Optional Drug-Drug Interaction [DDI] Substudy
|
Tablets taken by mouth.
Tablets taken by mouth
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
(Part 1A and 1B) Dose limiting toxicity (DLTs) associated with S241656 during the first cycle of treatment
大体时间:Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1A and 1B) Number of Adverse Events (AEs)
大体时间:Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of Serious Adverse Events (SAEs)
大体时间:Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Severity of AEs
大体时间:Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Severity of SAEs
大体时间:Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Duration of AEs
大体时间:Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Duration of SAEs
大体时间:Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of changes in safety laboratory results
大体时间:Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of changes in physical examination
大体时间:Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of dose reductions due to AEs
大体时间:Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of dose interruptions due to AEs
大体时间:Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of dose delays due to AEs
大体时间:Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of study withdrawals due to AEs
大体时间:Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1B only) Maximum concentration (Cmax) of S241656
大体时间:Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Cmax of metabolite S243796
大体时间:Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Time corresponding to Cmax (Tmax) of S241656
大体时间:Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Tmax of metabolite S243796
大体时间:Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Terminal half-life (t1/2) of S241656
大体时间:Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) t1/2 of metabolite S243796
大体时间:Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Area under the curve (AUC) of S241656
大体时间:Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) AUC of metabolite S243796
大体时间:Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
(Part 1A only) Cmax of S241656
大体时间:Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) Cmax of metabolite S243796
大体时间:Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) Tmax of S241656
大体时间:Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) Tmax of metabolite S243796
大体时间:Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) AUC of S241656
大体时间:Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) AUC of metabolite S243796
大体时间:Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) t1/2 of S241656
大体时间:Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) t1/2 of metabolite S243796
大体时间:Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A and 1B) Complete remission (CR)
大体时间:Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Complete remission with incomplete hematologic recovery (CRi)
大体时间:Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Morphologic leukemia free state (MLFS)
大体时间:Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Complete remission with partial hematologic recovery (CRh)
大体时间:Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Partial response (PR)
大体时间:Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Objective response (OR)
大体时间:Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Composite complete remission (CRc)
大体时间:Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Red blood cell (RBC) and platelet transfusion independence for at least 8 weeks
大体时间:Through end of treatment, up to approximately 4 years
|
In participants with AML or MDS/AML only
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Duration of response (DOR)
大体时间:Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Time to response (TTR)
大体时间:Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Event free survival (EFS)
大体时间:Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Overall survival (OS)
大体时间:Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Marrow response
大体时间:Through end of treatment, up to approximately 4 years
|
In participants with CMML only
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of participants with erythroid-, neutrophil-, platelet or spleen-response
大体时间:Through end of treatment, up to approximately 4 years
|
In participants with CMML only
|
Through end of treatment, up to approximately 4 years
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- S241656-292
- 2025-525128-88-00 (克蒂斯)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.
Access can be requested for all interventional clinical studies:
- used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
- where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.
In addition, access can be requested for all interventional clinical studies in patients:
- sponsored by Servier
- with a first patient enrolled as of 1 January 2004 onwards
- for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.
IPD 共享时间框架
IPD 共享访问标准
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.